Stock comparison
Halozyme Therapeutics
Moderna
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
MRNA
Moderna
Market cap
$18.6B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | MRNA | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 21F | HALO |
| Benjamin Graham | 83A | 47D | HALO |
| Philip Fisher | 65B | 27F | HALO |
| Peter Lynch | 53D | 4F | HALO |
| Joel Greenblatt | 40D | 2F | HALO |
| Charlie Munger | 80C | 19F | HALO |
| Terry Smith | 84A | 19F | HALO |
Side-by-side metrics
| Metric | HALO | MRNA |
|---|---|---|
| Market cap | $8.1B | $18.6B |
| P/E (TTM) | 24.0x | - |
| EV/EBIT | 10.2x | - |
| ROIC (TTM) | 23.65% | -37.32% |
| Gross margin | 81.24% | -13.89% |
| Net margin | 23.13% | -143.55% |
| Revenue CAGR 5y | 33.23% | -42.46% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs -42.46%+178%
- ROIC (TTM)23.65%vs -37.32%+163%
- Gross margin81.24%vs -13.89%+117%
- Net margin23.13%vs -143.55%+116%
MRNA leads on
- EV/EBIT-vs 10.2x+160%
- P/E (TTM)-vs 24.0x+125%
- Debt / Equity0.2xvs 1.0x+82%
- Market cap$18.6Bvs $8.1B+56%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.